Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01358734 | A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia | completed | Phase 2 | 88 | CelgeneINDUSTRY | 2 | Jun 25, 2019 | clinicaltrials |
| NCT00946270 | Pomalidomide for Myelofibrosis Patients | completed | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2019 |
| NCT01294618 | Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia(NILOPEG) | completed | Phase 2 | 60 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2019 | clinicaltrials |
| NCT00414310 | Decitabine (DAC) w/ or w/o Valproic Acid (VPA) in Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 153 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00475020 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT02311569 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation | completed | Phase 2 | 39 | Swiss Cancer InstituteOTHER | 1 | May 15, 2019 | clinicaltrials |
| NCT00413166 | All-trans Retinoic Acid, and Arsenic +/- Idarubicin | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT01392989 | Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders | completed | Phase 2 | 44 | Everett MeyerOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT00397579 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 11 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT00796562 | Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy | completed | Phase 2 | 107 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT00520130 | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01175785 | Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | completed | Phase 2 | 15 | Nohla Therapeutics, Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01165996 | Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 4, 2019 | clinicaltrials |
| NCT02076191 | Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML | completed | Phase 1 / Phase 2 | 49 | John MascarenhasOTHER | 1 | Feb 28, 2019 | clinicaltrials |
| NCT00416598 | Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 546 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2019 | clinicaltrials |
| NCT00766116 | Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 50 | University of California, San DiegoOTHER | 1 | Feb 18, 2019 | clinicaltrials |
| NCT01687387 | Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)(EFFIKIR) | completed | Phase 2 | 152 | Innate PharmaINDUSTRY | 1 | Feb 8, 2019 | clinicaltrials |
| NCT01729845 | Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 52 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 7, 2019 | clinicaltrials |
| NCT01807598 | Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia | completed | Phase 2 | 10 | Jason Robert GotlibOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02296242 | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 53 | BioMed Valley Discoveries, IncINDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01408563 | Reduced Intensity Double Umbilical Cord Blood Transplantation | completed | Phase 2 | 33 | Massachusetts General HospitalOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02208037 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | completed | Phase 2 | 279 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Jan 23, 2019 | clinicaltrials |
| NCT02019069 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 11 | Rondeep BrarOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01720264 | Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant | completed | Phase 2 | 15 | Sherif S. FaragOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT00831974 | Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis | completed | Phase 2 | 23 | AB ScienceINDUSTRY | 0 | Dec 11, 2018 | clinicaltrials |
| NCT00840346 | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)(PANOBIDARA) | completed | Phase 1 / Phase 2 | 46 | PETHEMA FoundationOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT01266369 | Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V Mutation | completed | Phase 2 | 21 | AB ScienceINDUSTRY | 0 | Dec 10, 2018 | clinicaltrials |
| NCT01824693 | Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia | completed | Phase 2 | 30 | Children's Oncology GroupNETWORK | 4 | Dec 5, 2018 | clinicaltrials |
| NCT00075010 | Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00903760 | Decitabine and Clofarabine in Higher Risk Myelodysplastic Syndromes (MDS) | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00709592 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | completed | Phase 2 | 42 | Virginia Commonwealth UniversityOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT00065143 | Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00038597 | Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML) | completed | Phase 2 | 13 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2018 | clinicaltrials |
| NCT01734304 | DC Vaccination for Postremission Therapy in AML | completed | Phase 1 / Phase 2 | 13 | Ludwig-Maximilians - University of MunichOTHER | 1 | Oct 12, 2018 | clinicaltrials |
| NCT01025154 | Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction | completed | Phase 2 | 63 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT00425477 | Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | completed | Phase 2 | 26 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 5, 2018 | clinicaltrials |
| NCT01621724 | WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study | completed | Phase 1 / Phase 2 | 7 | Cell Medica LtdINDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01687400 | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | completed | Phase 2 | 114 | Washington University School of MedicineOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02282215 | Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia | completed | Phase 2 | 163 | Cellerant TherapeuticsINDUSTRY | 1 | Sep 27, 2018 | clinicaltrials |
| NCT00001873 | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | completed | Phase 2 | 102 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00061581 | Experimental Bone Marrow Transplant Protocol | completed | Phase 2 | 14 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00233454 | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia | completed | Phase 2 | 26 | Jason Robert GotlibOTHER | 1 | Sep 20, 2018 | clinicaltrials |
| NCT00352001 | Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes | completed | Phase 1 / Phase 2 | 37 | Mikkael Sekeres MDOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2019source: clinicaltrials